Curium and Lantheus Agree to $8B Merger to Form Radiopharmaceutical Giant
The $8B deal combines two major radiopharmaceutical companies, expanding their global reach across oncology, neurology, and cardiology.
Curium and Lantheus have signed a definitive agreement to merge in an $8 billion deal that would create one of the world's largest radiopharmaceutical companies, the firms announced. The combined entity would compete across three major therapeutic areas — oncology, neurology, and cardiology — positioning it as a dominant force in a fast-growing medical imaging and targeted therapy sector.
The merger would extend the newly formed company's footprint to more than 70 countries, significantly broadening the geographic reach of both organizations. Radiopharmaceuticals — drugs that use radioactive isotopes for both diagnosis and treatment — have drawn intense investor and industry interest in recent years as precision medicine advances and demand for targeted cancer therapies accelerates.
Read more Visa Acquires Cybersecurity Firm BioCatch for $2.4 Billion →
The combination of Curium and Lantheus brings together complementary pipelines and commercial operations that span diagnostic imaging agents and next-generation therapeutic radiopharmaceuticals. Industry analysts have noted that scale is increasingly critical in this space, where manufacturing complexity, regulatory hurdles, and isotope supply chains favor larger, well-capitalized players.
While financial terms beyond the headline valuation were not disclosed, the $8 billion figure underscores just how rapidly the radiopharmaceutical market has matured from a niche segment into a strategic battleground for major healthcare and pharmaceutical investors. The deal is expected to reshape competitive dynamics globally as the two companies integrate their respective strengths in research, production, and distribution.
Continue reading at GlobalNewswire.
